This site provides INTERCEPT product information for International audiences Select your region
The report states that transfusion-transmitted bacterial infections are likely underdiagnosed because recipients are often given broad spectrum antibiotics or have underlying medical conditions that increase sepsis risk, or the septic reaction might not be attributed to the transfusion. It further recommends that blood suppliers and hospitals consider additional mitigation strategies, including pathogen inactivation.
The cases were recently published in CDC’s Morbidity and Mortality Weekly Report1.
Implementation of evidence-based strategies, including pathogen inactivation, rapid detection devices, and modified screening of bacterial culture protocols can mitigate the risk for bacterial contamination of platelets.
While in the hospital, the ultimate priority should be safeguarding patients. INTERCEPTTM Blood System for Platelets can be that life-saving device, helping to improve patient outcomes.
Want to stay updated on the latest pathogen inactivation news?
You can receive our highlights by subscribing to our newsletter.
Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.
Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.
© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0